Cancer Metabolism: Molecular Targeting and Implications for Therapy
Development of an effective anticancer therapeutic necessitates the selection of cancer-related or cancer-specific pathways or molecules that are sensitive to intervention. Several such critical yet sensitive molecular targets have been recognized, and their specific antagonists or inhibitors valida...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
Year of Publication: | 2017 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 electronic resource (114 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993543894104498 |
---|---|
ctrlnum |
(CKB)4100000002484755 (oapen)https://directory.doabooks.org/handle/20.500.12854/42642 (EXLCZ)994100000002484755 |
collection |
bib_alma |
record_format |
marc |
spelling |
Shanmugasundaram Ganapathy-Kanniappan auth Cancer Metabolism: Molecular Targeting and Implications for Therapy Cancer Metabolism Frontiers Media SA 2017 1 electronic resource (114 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics Development of an effective anticancer therapeutic necessitates the selection of cancer-related or cancer-specific pathways or molecules that are sensitive to intervention. Several such critical yet sensitive molecular targets have been recognized, and their specific antagonists or inhibitors validated as potential therapeutics in preclinical models. Yet, majority of anticancer principles or therapeutics show limited success in the clinical translation. Thus, the need for the development of an effective therapeutic strategy persists. “Altered energy metabolism” in cancer is one of the earliest known biochemical phenotypes which dates back to the early 20th century. The German scientist, Otto Warburg and his team (Warburg, Wind, Negelein 1926; Warburg, Wind, Negelein 1927) provided the first evidence that the glucose metabolism of cancer cells diverge from normal cells. This phenomenal discovery on deregulated glucose metabolism or cellular bioenergetics is frequently witnessed in majority of solid malignancies. Currently, the altered glucose metabolism is used in the clinical diagnosis of cancer through positron emission tomography (PET) imaging. Thus, the “deregulated bioenergetics” is a clinically relevant metabolic signature of cancer cells, hence recognized as one of the hallmarks of cancer (Hanahan and Weinberg 2011). Accumulating data unequivocally demonstrate that, besides cellular bioenergetics, cancer metabolism facilitates several cancer-related processes including metastasis, therapeutic resistance and so on. Recent reports also demonstrate the oncogenic regulation of glucose metabolism (e.g. glycolysis) indicating a functional link between neoplastic growth and cancer metabolism. Thus, cancer metabolism, which is already exploited in cancer diagnosis, remains an attractive target for therapeutic intervention as well. The Frontiers in Oncology Research Topic “Cancer Metabolism: Molecular Targeting and Implications for Therapy” emphases on recent advances in our understanding of metabolic reprogramming in cancer, and the recognition of key molecules for therapeutic targeting. Besides, the topic also deliberates the implications of metabolic targeting beyond the energy metabolism of cancer. The research topic integrates a series of reviews, mini-reviews and original research articles to share current perspectives on cancer metabolism, and to stimulate an open forum to discuss potential challenges and future directions of research necessary to develop effective anticancer strategies. English Tumor microenvironment metastasis glycolysis immunotherapy epigenetic regulation metabolic reprogramming Warburg effect 2-88945-322-7 |
language |
English |
format |
eBook |
author |
Shanmugasundaram Ganapathy-Kanniappan |
spellingShingle |
Shanmugasundaram Ganapathy-Kanniappan Cancer Metabolism: Molecular Targeting and Implications for Therapy Frontiers Research Topics |
author_facet |
Shanmugasundaram Ganapathy-Kanniappan |
author_variant |
s g k sgk |
author_sort |
Shanmugasundaram Ganapathy-Kanniappan |
title |
Cancer Metabolism: Molecular Targeting and Implications for Therapy |
title_full |
Cancer Metabolism: Molecular Targeting and Implications for Therapy |
title_fullStr |
Cancer Metabolism: Molecular Targeting and Implications for Therapy |
title_full_unstemmed |
Cancer Metabolism: Molecular Targeting and Implications for Therapy |
title_auth |
Cancer Metabolism: Molecular Targeting and Implications for Therapy |
title_alt |
Cancer Metabolism |
title_new |
Cancer Metabolism: Molecular Targeting and Implications for Therapy |
title_sort |
cancer metabolism: molecular targeting and implications for therapy |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA |
publishDate |
2017 |
physical |
1 electronic resource (114 p.) |
isbn |
2-88945-322-7 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT shanmugasundaramganapathykanniappan cancermetabolismmoleculartargetingandimplicationsfortherapy AT shanmugasundaramganapathykanniappan cancermetabolism |
status_str |
n |
ids_txt_mv |
(CKB)4100000002484755 (oapen)https://directory.doabooks.org/handle/20.500.12854/42642 (EXLCZ)994100000002484755 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
Cancer Metabolism: Molecular Targeting and Implications for Therapy |
container_title |
Frontiers Research Topics |
_version_ |
1759307578098057217 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03653nam-a2200373z--4500</leader><controlfield tag="001">993543894104498</controlfield><controlfield tag="005">20230221133615.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2017 xx |||||o ||| eneng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4100000002484755</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/42642</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994100000002484755</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Shanmugasundaram Ganapathy-Kanniappan</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cancer Metabolism: Molecular Targeting and Implications for Therapy</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Cancer Metabolism</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (114 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Development of an effective anticancer therapeutic necessitates the selection of cancer-related or cancer-specific pathways or molecules that are sensitive to intervention. Several such critical yet sensitive molecular targets have been recognized, and their specific antagonists or inhibitors validated as potential therapeutics in preclinical models. Yet, majority of anticancer principles or therapeutics show limited success in the clinical translation. Thus, the need for the development of an effective therapeutic strategy persists. “Altered energy metabolism” in cancer is one of the earliest known biochemical phenotypes which dates back to the early 20th century. The German scientist, Otto Warburg and his team (Warburg, Wind, Negelein 1926; Warburg, Wind, Negelein 1927) provided the first evidence that the glucose metabolism of cancer cells diverge from normal cells. This phenomenal discovery on deregulated glucose metabolism or cellular bioenergetics is frequently witnessed in majority of solid malignancies. Currently, the altered glucose metabolism is used in the clinical diagnosis of cancer through positron emission tomography (PET) imaging. Thus, the “deregulated bioenergetics” is a clinically relevant metabolic signature of cancer cells, hence recognized as one of the hallmarks of cancer (Hanahan and Weinberg 2011). Accumulating data unequivocally demonstrate that, besides cellular bioenergetics, cancer metabolism facilitates several cancer-related processes including metastasis, therapeutic resistance and so on. Recent reports also demonstrate the oncogenic regulation of glucose metabolism (e.g. glycolysis) indicating a functional link between neoplastic growth and cancer metabolism. Thus, cancer metabolism, which is already exploited in cancer diagnosis, remains an attractive target for therapeutic intervention as well. The Frontiers in Oncology Research Topic “Cancer Metabolism: Molecular Targeting and Implications for Therapy” emphases on recent advances in our understanding of metabolic reprogramming in cancer, and the recognition of key molecules for therapeutic targeting. Besides, the topic also deliberates the implications of metabolic targeting beyond the energy metabolism of cancer. The research topic integrates a series of reviews, mini-reviews and original research articles to share current perspectives on cancer metabolism, and to stimulate an open forum to discuss potential challenges and future directions of research necessary to develop effective anticancer strategies.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Tumor microenvironment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cancer Metabolism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glycolysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epigenetic regulation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metabolic reprogramming</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Warburg effect</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88945-322-7</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-03-03 01:52:09 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2018-03-10 17:16:05 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337440820004498&Force_direct=true</subfield><subfield code="Z">5337440820004498</subfield><subfield code="8">5337440820004498</subfield></datafield></record></collection> |